Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024:1457:165-184.
doi: 10.1007/978-3-031-61939-7_9.

Vaccination and Therapeutics

Walid Shaban Abdella  1 , Ahmed Nabil Selim  2 , Sheeren Diab  3 , Esraa Qobeia  4 , Akram Fekry Elgazzar  5
Affiliations
Review

Vaccination and Therapeutics

Walid Shaban Abdella et al. Adv Exp Med Biol. 2024.

Abstract

In the wake of the novel Coronavirus, it has become imperative to develop vaccines that can alert our immune system to the virus, hence reducing the severity of disease if exposed to it. Different types of vaccines have been studied in this respect, such as nucleic acid vaccines (mRNA and DNA vaccines), vector-based vaccines, whole-virus vaccines (inactivated virus and live-attenuated vaccine), as well as protein subunits vaccines. The results have demonstrated that these vaccines are efficient against both the original strain and emerging variants. Furthermore, they also proved their safety with no grave adverse events. Despite this, hesitancy toward taking these vaccines is still present among certain groups in society due to various factors. Special emphasis has been placed on studies concerning pregnant women, children, elderly people, and immunocompromised individuals where efficacy and safety were proven.

Keywords: Ad26.COV2.S; Adenovirus; COVID-19; Coronavirus; DNA; EpiVacCorona; Glycoprotein; NVX-CoV2373; Novavax; Vaccines; mRNA.

PubMed Disclaimer

References

    1. Abu-Raddad LJ et al (2021) Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 385(2):187–189 - PubMed - DOI
    1. Abu-Raddad LJ et al (2022) Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar. N Engl J Med 386(19):1804–1816 - PubMed - DOI
    1. Ai-ris YC et al (2021) Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. JAMA 325(23):2370–2380 - DOI
    1. Anand P, Stahel VP (2021) The safety of COVID-19 mRNA vaccines: a review. Patient Saf Surg 15(1):1–9
    1. Andrew MK et al (2019) Influenza vaccination in older adults: recent innovations and practical applications. Drugs Aging 36:29–37 - PubMed - DOI

LinkOut - more resources